ClinicalTrials.Veeva

Menu
R

Remington-Davis, Inc | Columbus, OH

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Orforglipron
LY3502970
Ritlecitinib
RTA 901
Tanezumab
LY3471851
Difamilast
Peramivir
Bimagrumab
Zidovudine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 44 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Not yet enrolling
Hypertension
Overweight or Obesity
Drug: Placebo
Drug: Orforglipron
New

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in partic...

Begins enrollment this month
Overweight
Obesity
Drug: Bimagrumab Placebo
Drug: Tirzepatide Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: LY3972406

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in t...

Enrolling
COVID-19 SARS-CoV-2 Infection
Drug: placebo
Drug: ibuzatrelvir
Locations recently updated

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...

Enrolling
Refractory or Unexplained Chronic Cough
Drug: NOC-110
Other: Placebo

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Pfizer logo
Lilly logo
Acrotech Biopharma logo
Merck Sharp & Dohme (MSD) logo
Nektar Therapeutics logo
Reata Pharmaceuticals logo
A
B
BioCryst logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems